<i>Ex vivo</i> assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations.
Ontology highlight
ABSTRACT: Sulbactam-durlobactam is approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Patients with serious Acinetobacter infections may require support with continuous renal replacement therapy (CRRT), which presents challenges for optimal dosing of antibiotics. Sulbactam-durlobactam dosing regimens were derived for this population using an ex vivo CRRT model and Monte Carlo simulation (MCS). Transmembrane clearance (CLTM) was determined in hemofiltration (CVVH) and hemodialysis (CVVHD) modes using the Prismaflex M100 and HF1400 hemofilter sets and with effluent rates of 1, 2, and 3 L/h. Pre-filter, post-filter blood, and effluent samples were c
SUBMITTER: Abouelhassan Y
PROVIDER: S-EPMC11784458 | biostudies-literature | 2025 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA